AG
ESPR

Aperio Group’s Esperion Therapeutics ESPR Stock Holding History

Aperio Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-614
Closed -$29K – 2455
2019
Q2 		$29K Buy
+614
New +$28.8K ﹤0.01% 2629
2018
Q2 		– Sell
-5,995
Closed -$434K – 2269
2018
Q1 		$434K Buy
5,995
+597
+11% +$43.8K ﹤0.01% 1763
2017
Q4 		$355K Hold
5,398
– – ﹤0.01% 1864
2017
Q3 		$271K Buy
5,398
+8
+0.1% +$386 ﹤0.01% 1971
2017
Q2 		$249K Buy
+5,390
New +$198K ﹤0.01% 1994

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aperio Group's ESPR Position: Q3 2019 in Review

Aperio Group sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 614 shares — an estimated $29K sold.

Aperio Group first reported a position in ESPR in Q2 2017 and held it in 5 quarters. The position peaked at $434K in Q1 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Aperio Group reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 614 Esperion Therapeutics shares in Q3 2019, an estimated $29K.
  • Aperio Group first reported a position in Esperion Therapeutics in Q2 2017 and held it in 5 quarters.
  • Aperio Group's Esperion Therapeutics position peaked at $434K in Q1 2018.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.